JAK Inhibitor Combinations

About OncoTracker

ONCOtracker is a privately held, early-stage biotech incubator with a core focus on diagnostics and therapeutic development for multiple myeloma and related B-cell disorders. Its primary assets include a clinically validated serum BCMA (sBCMA) ELISA testing service, a proprietary biobank, and early-stage therapeutic programs involving JAK and gamma secretase inhibitors. The company leverages the deep clinical and research network of its founder, Dr. James Berenson, integrating a specialty clinic, a CRO, and a non-profit research institute to accelerate innovation from bench to bedside.

Therapeutic Areas